Purpose The PET tracer, 124 I-cG250, directed against carbonic anhydrase IX (CAIX) shows promise for presurgical diagnosis of clear-cell renal cell carcinoma (ccRCC) (Divgi et al. in Lancet Oncol 8:304-310, 2007; Divgi et al. in J Clin Oncol 31:187-194, 2013 I-cG250 using a human ccRCC cell line (SK-RC-38) to characterize the binding affinity and internalization kinetics of the two tracers in vitro. Serial PET imaging was performed in mice bearing subcutaneous ccRCC tumors to simultaneously detect and quantify time-dependent tumor uptake in vivo. Using the known specific activities of the two tracers, the equilibrium rates of antibody internalization and turnover in the tumors were derived from the PET images using nonlinear compartmental modeling. Results The two tracers demonstrated virtually identical tumor cell binding and internalization but showed markedly different retentions in vitro. Superior PET images were obtained using Zr-cG250 is likely to provide highquality PET images and may be a useful tool to quantify CAIX/cG250 receptor turnover and cG250-accessible antigen density noninvasively in humans.
Zr-cG250 using a human ccRCC xenograft tumor model in mice. We believe that this unique model better relates quantitative imaging data to the salient biological features of tumor antibody-antigen binding and turnover. Methods We conducted experiments with 89 Zr-cG250 and 124 I-cG250 using a human ccRCC cell line (SK-RC-38) to characterize the binding affinity and internalization kinetics of the two tracers in vitro. Serial PET imaging was performed in mice bearing subcutaneous ccRCC tumors to simultaneously detect and quantify time-dependent tumor uptake in vivo. Using the known specific activities of the two tracers, the equilibrium rates of antibody internalization and turnover in the tumors were derived from the PET images using nonlinear compartmental modeling. Results The two tracers demonstrated virtually identical tumor cell binding and internalization but showed markedly different retentions in vitro. Superior PET images were obtained using 89 Zr-cG250, owing to the more prolonged trapping of the radiolabel in the tumor and simultaneous washout from normal tissues. Estimates of cG250/CAIX complex turnover were 1.35 -5.51×10 12 
Introduction
The chimeric monoclonal antibody cG250 described by Oosterwijk and colleagues targets CAIX, a transmembrane protein involved in control of interstitial pH in normal human tissues and tumors [1] . The antigen itself is under the regulatory control of hypoxia-inducible factor alpha and is upregulated uniformly in clear-cell renal cell carcinoma (ccRCC) due to loss of the von Hippel-Lindau tumor suppressor. The cG250 antibody has been used as a targeting vector for diagnostic and therapeutic radionuclides for management of advanced ccRCC [2] [3] [4] . For example, diagnostic PET imaging with 124 I-cG250 has been reported to allow measurement of disease burden and distinguish clear-cell cancer from other histologies. Noninvasive staging is especially important in older patients with impaired renal function in whom surgery or even biopsy might be hazardous. Also, Stillebroer et al. recently conducted a phase 1 radioimmunotherapy study with 177 Lu-cG250 in patients with progressive metastatic ccRCC. Of 23 patients, 17 (74 %) had stable disease 3 months following treatment and one patient showed a partial response that lasted for 9 months [5] .
Rational design of antibody-targeted tracers and drugs (such as cG250 conjugates) requires an understanding of the spatiotemporal disposition of the antibody in vivo and the inherently variable fate of the antibody-conjugated cargo (e.g. I-iodotyrosine is rapidly expelled from the cell after lysosomal degradation [6] . Conversely, "residualizing" radiometals such as 111 In and Lu are retained by the cell in the form of low molecular weight catabolites [7] . This phenomenon has been demonstrated to have clinical consequences for cG250/CAIX imaging; for example, Brouwers et al. In-cG250 in RCC metastases and found that the total number of lesions revealed was greater with the 111 In-labeled tracer due to the higher activity overall in the lesions and the higher tumor-to-blood ratios [8] .
The longer-lived radiometal 89 Zr has emerged as an attractive alternative to 124 I owing to its residualizing properties in vivo [9, 10] study in mice bearing ccRCC tumors directly comparing   89   ZrcG250 and   124 I-cG250, and found differences in tracer uptake depending on the tumor model [11] . Specifically, these authors observed significantly higher uptake of 89 Zr-cG250 compared with 124 I-cG250 in NU-12 tumors, while there were insignificant differences in uptake between tracers in the SK-RC-52 tumor model. These studies suggest that while residualizing nuclides are generally better suited to the G250/CAIX biology, factors such as antigen density at the tumor, antigen present within normal tissues such as the gastric mucosa, and prolonged retention of radiometals in liver and spleen, may favor nonresidualizing nuclides under some circumstances.
In this study we compared Zr-cG250 using a nonlinear compartmental model to facilitate quantitative comparison of time-dependent uptake and antibody turnover. This model also better relates the imaging data to biological features of antibody-receptor binding such as internalization of the antibody-antigen complex. The model also supports a preliminary assessment of the potential benefits of radiolabeling cG250 with 89 Zr versus 124 I as a PET tracer for ccRCC. We conducted in vitro cell binding assays using the human ccRCC line SK-RC-38 to determine the kinetics of antigen-antibody binding and evaluate the effect of the radionuclide on the activity of the antibody (e.g. K d , B max , immunoreactivity). Next, we conducted serial PET imaging and biodistribution experiments to evaluate the fate of each tracer in athymic nude mice bearing subcutaneous (s.c.) SK-RC-38 xenografts. Each tracer was evaluated at administered doses of less than 100 μg, expected to be subsaturating based on the observed in vitro B max and occupancy observed (i.e. absolute uptake) during in vivo experiments. A description of initial experiments in abstract form was presented at the 2012 World Molecular Imaging Congress, Dublin, Republic of Ireland [12] .
Materials and methods

Reagents, antibodies, cells, and mice
Unless otherwise noted, all chemicals were obtained from Sigma-Aldrich (Milwaukee, WI) or Fisher Scientific (Pittsburg, PA) and used without further purification. Ultrapure water (≥18.2 MΩ ·cm) was obtained from an Alpha-Q Ultrapure water system (Millipore). The chimeric monoclonal antibody cG250 and the RCC line SK-RC-38 were supplied by the Ludwig Institute for Cancer Research Center (New York, NY). Cells were grown by serial passage and maintained in RPMI medium supplemented with 1 % glutamine, 50 U/mL penicillin, 50 U/mL streptomycin, and 10 % heat-inactivated fetal bovine serum at 37°C in a 5 % 
Antibody conjugation and radiolabeling
The cG250 antibody was conjugated with isothiocyanatobenzyldesferrioxamine (SCN-DFO; Macrocyclics, Dallas, TX) and radiolabeled using methods previously described by Vosjan et al. [13] . 89 Zr was provided by the Memorial Sloan-Kettering Radiochemistry & Molecular Imaging Probes Core Facility according to previously reported methods at a specific activity (SA) in the range 195 -497 MBq/μg [14] . The resulting DFO-cG250 bioconjugate showed a DFO-toantibody mole ratio of 3.25±0.07, as assessed by isotope titration according to the method of Anderson et al. [15] . DFO-cG250 was radiolabeled with 89 Zr under neutral buffer conditions and gentle incubation (room temperature for 1 h) to a final SA of about 360 MBq/mg with radiochemical yields of ≥80 %. The radiochemical purity was determined to be >99 % by instant thin-layer chromatography (I-TLC) using 5 mM DTPA, pH 5.0. The stability of 89 Zr-cG250 in human serum was evaluated in vitro over 11 days at 37°C by I-TLC, showing that ≥97.8 % of the total 89 Zr activity remained in a form consistent with 89 ZrcG250 over the course of the study.
124
I was either provided in-house or purchased commercially (IBA Molecular). The radiochemical yield of 131/124 I-cG250 was in the range 58 -60 %, with the SA in the range 122 -174 MBq/mg and with radiochemical purity consistently >99 % by I-TLC using 10 % trichloroacetic acid (TCA). The in vivo stability of 124 I-cG250 was evaluated in normal mice (no blocking of thyroid) to determine tracer de-iodination in the absence of tumor. I-TLC analysis with 10 % TCA of blood up to 3 days postinjection (p.i.) suggested that 124 I-cG250 was stable in the circulation, as >99 % of the total 124 I activity was TCAinsoluble, consistent with intact protein (i.e.
124 I-cG250). The whole-body activity (WBA) data up to 10 days p.i. were fitted to a monoexponential function, yielding a half-life of 52 h (R 2 = 0.98).
I and 111
In were obtained from Nordion. I-cG250) were prepared according to clinical protocols [16, 17] . Activities were measured using a CRC-15R dose calibrator (Capintec, Ramsey, NJ). Gamma counting was conducted using an automatic well counter (Perkin Elmer Wallac Wizard 3" automatic gamma counter) calibrated (in terms of counts per minute per kilobecquerel) for the respective isotopes.
Cell binding, internalization, and catabolism of radiolabeled antibodies Saturation binding assays were performed as previously described [18, 19] and analyzed using Scatchard analysis and a nonlinear regression saturation binding (one-site, specificbinding) method, following subtraction of nonspecific binding (Prism, GraphPad Software, Inc.). Immunoreactivity was determined using the method of Lindmo et al. [20] . For internalization assays, cells were harvested and added to 12-well plates (500,000 cells/well, 1 mL). After allowing cells to seed overnight, 70 ng of radiolabeled antibody in 10μL was added to each well (47 pM final concentration) and incubated at either 37°C or 4°C. At various incubation time-points between 15 min and 48 h at 37°C and between 15 min and 24 h at 4°C (n = 4), medium was removed and the cells gently washed with ice-cold phosphate-buffered saline followed by ice-cold 0.1 M acetic acid + 0.1 M glycine (1 min incubation) and 1 M NaOH (5 min incubation). The activity in all media and washes was assayed by counting in the gamma counter. At 48 h, aliquots of harvested media were assayed by methanol precipitation to determine the extent of radiolabeled antibody degradation and catabolism following incubation with cells [21] .
Mouse RCC xenograft models and PET imaging For PET imaging studies, mice bearing s.c. SK-RC-38 xenografts were injected intravenously with 89 Zr-cG250 (14.6 -15.0 MBq, 40 μg, 267 pmol) or 124 I-cG250 (11.8 -12.6 MBq, 100μg, 667 pmol) in 200μL saline + 1 % bovine serum albumin (BSA). At various time-points after injection ranging from 5 to 264 h for 89 Zr and from 7 to 240 h for 124 I, mice were scanned using a microPET Focus 120 scanner (Concorde Microsystems, Knoxville, TN) while under anesthesia using a mixture of 1.5 -2 % isoflurane (Baxter Healthcare, Deerfield, IL) and air. In addition, animals were assayed for WBA in the dose calibrator at each imaging time-point as described above. Imaging data were acquired using an energy window of 350 -700 keV and a coincidence timing window of 6 ns; the scan times were adjusted to acquire a minimum of 20 million coincidence events up to a maximum of 1 h beyond 7 days p.i. Data were sorted into twodimensional histograms by Fourier rebinning, and images were reconstructed by filtered back-projection with a 128× 128×6 matrix (0.72×0.72×1.33 mm). The resulting images were parameterized (as percent injected dose per gram, %ID/ g) by first converting the voxel counting rates to activity concentrations using empirically determined calibration factors for each isotope, followed by decay correction to the time of injection and normalization to the administered activity. Two-dimensional regions of interest (ROI) were manually drawn for tumor and blood pool (the heart region) using ASIPro VM™ software (Concorde Microsystems). Tumor ROI values were corrected for the partial-volume effect using phantom-derived volume-dependent recovery coefficients and calculated tumor volumes (V), calculated as V = (π/
into mice bearing s.c. SK-RC-38 tumors. Count data were corrected for background and decay to the time of injection and then converted to activity using the isotopespecific calibration factor. Uptake for each tissue sample was calculated by normalization to the total activity injected and expressed as %ID/g.
Statistical analysis
Differences in tissue uptake between cohorts were analyzed for statistical significance by Student's t test for paired data. Two-sided significance levels were calculated and p<0.05 was considered statistically significant. 
Results
In vitro characterization of radiolabeled cG250
For all radiolabeled antibodies, the immunoreactivity was observed to be >90 % using the Lindmo assay. Scatchard analysis of binding capacity (B max ) of I were observed to be present on the cell surface at tracer concentrations of 3 % and 1 % of the total added activity after 24 h, respectively, and remain unchanged at 48 h (Fig. 2) . Internalization data obtained up to 48 h were fitted to a monoexponential function, and the bound antibody internalization rate was determined to be 20 % per hour for both radiolabeled forms of the antibody. At 48 h, the percent of activity in harvested media that was methanol-precipitable for ZrcG250 can lead to high-contrast imaging of a s.c. model of ccRCC in vivo, but with notable differences in tumor uptake and retention of the tracer. Tumor activity concentrations were expressed as the maximum %ID/g in manually drawn twodimensional tumor-contouring ROIs (Fig. 4) . At 5 h p.i., the activity concentrations of both the 124 I and 89 Zr radiolabels were sufficiently high relative to background to produce highcontrast tumor images (due, in part, to the location of the xenograft in the flank and the absence of significant contiguous background activity), but contrast was improved at 24 h p.i. Uptake of 89 Zr-cG250 increased over 48 h p.i. to a plateau of about 20 %ID/g, which persisted to the last imaging timepoint at 11 days p.i. With 124 I-cG250, a peak uptake of about 5 %ID/g was observed at 5 -24 h p.i., with subsequent washout to about 2 %ID/g at 10 days p.i. Time-activity curves for thyroid uptake of 124 I are provided in Supplementary Fig. S1 . The whole-body clearance kinetics of each tracer were determined in tumor-bearing mice. The effective in vivo I-cG250 were found in the liver (p < 0.05), spleen, kidney and bone (all p < 0.005), presumably due to the metabolism of radiometal complexes in vivo and the affinity of bone for free 89 Zr [22] . Such nonspecific tracer uptake in normal tissue, especially in the liver and bone, are of particular concern for presurgical diagnosis of advanced metastatic disease, as well as dosimetry planning for radioimmunotherapy [23] .
Results of the nonlinear compartmental modeling of 89 ZrcG250 and 124 I-cG250 in tumor-bearing mice are shown in Fig. 6 . The "best-fit" model parameters were as follows: for 89 Zr-cG250, k a = 3.5×10 10 h
, and k(3,2) = 0.20 h
, and k(3,2) = 0.20 h 
Discussion
Our aim was to model the relationship between antibodyantigen binding and internalization properties using quantitative noninvasive PET imaging with two distinct radiotracers in a single preclinical mouse xenograft model of ccRCC. It has been previously documented that conjugating cG250 with a residualizing radiotracer will give higher contrast imaging of RCC tumors in mice. [24] . We reasoned that a more comprehensive pair-wise comparison of 89 Zr-cG250 and 124 I-cG250 both in vitro and in vivo would allow the development of a kinetic model that could take into account (1) the specific activity of tracers in vitro, and (2) the rate of degradation and extent of release of tracer metabolites from the cell. We . In all cases, the model yields reasonably good fits to the data believe this approach leads to a more accurate estimation of the residence time and antibody-antigen turnover kinetics in tumor in vivo. We began our study with an evaluation of the in vitro disposition of the two tracers using the human ccRCC cell line SK-RC-38. Both 89 Zr-cG250 and 124 I-cG250 had binding properties derived from saturation binding studies that were within the same order of magnitude (5.33 ± 0.52 nM and 1.51 ± 0.08 nM, respectively), as were the number of binding sites per cell (218,000 ± 5,600 and 167,000 ± 3,900, respectively). Next, a continuous uptake assay was performed to determine the kinetics of surface binding and subsequent internalization. We observed that the internalized fraction of both 89 Zr-cG250 and 124 I-cG250 gradually increased at the same rate (20 % per hour) to a maximum of 60 -70 % of total added activity at 24 h, which remained unchanged at 48 h. In addition, a very small fraction of membrane-bound activity (<5 %, up to 48 h) was isolated using a low-pH wash at all time-points. These findings suggest that both radioantibody forms are rapidly internalized and accumulate in the cell, ultimately trafficking to the lysosome, where the antigenantibody complexes are catabolized [25] .
To further characterize the antibody-antigen turnover in vitro, aliquots of the cellular supernatants were subjected to methanol precipitation after incubation for 48 h at 37°C. Compared with 89 Zr, a greater abundance of iodine metabolites appeared in the extracellular medium (about 50 % of total activity was methanol-insoluble/protein-associated at 48 h). These observations are consistent with previous in vitro studies of radiolabeled G250 stability [26] as well as G250/CAIX internalization and tracer fate using human RCC lines [17] . The identical serum stability of the tracers indicated little change in the status of the radiometal antibody but a decrease in the radioiodinated fraction of antibody, consistent with the concept that it was low-molecular weight forms of radioiodine which were released from the cells.
Mice bearing RCC xenografts were treated with 89 ZrcG250 or 124 I-cG250 and serially imaged by PET over the course of 10 -11 days p.i. to determine the kinetics of tracer uptake in the tumor and rates of clearance from the vascular compartment. While both tracers allowed high-contrast imaging of ccRCC, the comparative intratumoral concentrations varied significantly from 5 h to 10 days p.i. This observation could not be explained by differences in clearance, as the biological half-lives as determined by quantitation of activity in the circulation were not significantly different. The washout of 124 I-tracer from the tumor due to RCC catabolism was supported by the observation of radioiodine accumulation in the thyroid observed during PET imaging as well as more rapid whole-body clearance.
In developing antibody-based therapies such as cytotoxic drug or radioimmunoconjugates, quantitatively characterizing the biology of the antibody-antigen interaction, internalization, and turnover is valuable [27] . Many groups have described kinetic models that provide insight into the relationship between the in vitro and in vivo behavior of antibodies [28] [29] [30] . By evaluating a particular antibody candidate using both residualizing and nonresidualizing radioactive labels (e.g. serial imaging with PET to noninvasively quantify tracer in tissue), the turnover kinetics can be determined and applied to a kinetic model that can estimate the residence time of a particular label as a function of dose. With efforts increasing to engineer antibodies that offer improved affinity, immunomodulatory response, or with desirable internalization kinetics (e.g. for CAIX [31] ), the use of a kinetic model can guide selection of the optimum antibody construct for a particular patient and application as well as the optimum patient-specific doses (in terms of moles). This can be applied not only to radiolabeled antibody forms but toxin-or drug-conjugated antibody constructs. If a residualizing radiolabel such as 89 Zr were incorporated into such a therapeutic antibody-drug construct, the tumor area under the curve for the radiolabel would serve as a surrogate metric of the drug area under the curve and thus could be used to plan and optimize antibodymediated drug therapy. In addition, insight into the effects of refining targeting strategies such as modulating intracellular delivery and traffic dynamics (e.g. with conjugation of membrane-destabilizing synthetic polymers such as poly(propylacrylic) acid [32] ) or antigen accessibility (e.g. with microtubule depolymerizing drugs in the case of PSMA targeting [33] ) can potentially be evaluated.
According to our studies, I. This information could be used to estimate CAIX/cG250 receptor turnover and cG250-accessible antigen density in clinical studies.
The development of this kinetic model was based on our prior studies of immunoPET in humans, which showed that in vivo the antigen targeting of antibody is driven by the law of mass action [34] . The modeling of this process requires saturable and therefore nonlinear kinetics dependent on the concentrations of free reactants and the antibody-antigen affinity. The resulting model (Fig. 1) can accommodate the biology of internalization of the antibody-antigen complex. In essence, the rate of uptake of the radiotracer, retention, and release can ultimately be determined from a noninvasive quantitative imaging assay such as PET.
Conclusion
By comparing the differential catabolism of the two radioantibody forms, 124 I-cG250 and 89 Zr-cG250, we determined the relationship between the biology of the cG250/ CAIX interaction and subsequent processes (internalization and catabolism). The distinct radioantibody formulations were virtually identical in terms of clearance from the blood, initial tumor binding and uptake, and rate of internalization of the cG250/CAIX antibody receptor complex. However, there were marked differences in the rate of clearance from tumor, with the 124 I atoms being cleared from tumor more than 17.5 times more rapidly than 
